Patents Represented by Attorney, Agent or Law Firm Wayne J. Dustman
-
Patent number: 7452874Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: January 8, 2007Date of Patent: November 18, 2008Assignee: SmithKline Beecham Corp.Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
-
Patent number: 7439342Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: January 8, 2007Date of Patent: October 21, 2008Assignee: Smith Kline Beecham Corp.Inventors: Kevin J. Duffy, Juan I. Luengo
-
Patent number: 7414040Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: June 6, 2003Date of Patent: August 19, 2008Assignee: SmithKline Beecham CorporationInventor: Dirk A. Heerding
-
Patent number: 7348339Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.Type: GrantFiled: March 21, 2003Date of Patent: March 25, 2008Assignee: Glaxo Group LimitedInventors: Nicholas Bailey, Mark James Bamford, Haifeng Cui, Stephen Garland, Krista B Goodman, Mark A Hilfiker, Dennis Lee, Terence Aaron Panchal, Robert A Stavenger, David Matthew Wilson, Jason Witherington
-
Patent number: 7335649Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: November 9, 2006Date of Patent: February 26, 2008Assignee: SmithKline Beecham CorporationInventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
-
Patent number: 7332481Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: January 5, 2007Date of Patent: February 19, 2008Assignee: SmithKline Beecham CorporationInventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan Luengo, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
-
Patent number: 7241783Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.Type: GrantFiled: December 19, 2001Date of Patent: July 10, 2007Assignees: SmithKline Beecham Corporation, Ligand PharmaceuticalInventors: Kevin J. Duffy, Juan I. Luengo, Stephen G. Miller, Julian Jenkins, Alan T. Price, Antony N. Shaw
-
Patent number: 7229640Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.Type: GrantFiled: December 18, 2001Date of Patent: June 12, 2007Assignee: SmithKline Beecham p.l.c.Inventors: Graham Stanley Leonard, David Philip Elder
-
Patent number: 7160870Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: May 24, 2001Date of Patent: January 9, 2007Assignees: SmithKline Beecham Corporation, Glaxo Group LimitedInventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
-
Patent number: 6969526Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.Type: GrantFiled: December 18, 2001Date of Patent: November 29, 2005Assignee: SmithKline Beecham p.l.c.Inventors: Graham Stanley Leonard, David Philip Elder
-
Patent number: 6939871Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6-alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, alkylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, arolC1-6alkyl, arylC1-6alkanoyl, a group R<3>OCO(CH2)s, R<3>CON(R&Type: GrantFiled: October 22, 2001Date of Patent: September 6, 2005Assignee: SmithKline Beecham p.l.c.Inventors: Christopher Norbert Johnson, Harshad Kantilal Rami, Geoffrey Stemp, Kevin Thewlis, Mervyn Thompson, Antonio Keuok Keong Vong
-
Patent number: 6875786Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: March 1, 2002Date of Patent: April 5, 2005Assignee: SmithKline Beecham CorporationInventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw
-
Patent number: 6720345Abstract: Compounds of formula (I), particularly a compound of formula (Ia), are non-peptide TPO mimetics, useful in the treatment of thrombocytopenia.Type: GrantFiled: May 3, 2002Date of Patent: April 13, 2004Assignee: SmithKline Beecham CorporationInventors: Juan I. Luengo, Kevin J. Duffy, Antony N. Shaw
-
Patent number: 6716985Abstract: Compounds of structure (1) are obtained by reduction of compounds of the structures: Compounds of structure (1), especially where Z is a hydrogen atom or a 3,4-methylenedioxyphenyl group, are important intermediates for inter alia paroxetine.Type: GrantFiled: May 3, 2002Date of Patent: April 6, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Victor Withold Jacewicz, Marvin Sungwhan Yu, Evgeny Shapiro
-
Patent number: 6699882Abstract: Paroxetine is adsorbed on a carrier to form a free-flowing powder useful for capsule filling or for tablet formulation; and used in therapy to treat depression.Type: GrantFiled: April 29, 2002Date of Patent: March 2, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Andrew Simon Craig, Neal Ward
-
Patent number: 6670387Abstract: Non-peptide TPO mimetics are disclosed, as well as a method of treating thrombocytopenia, in a mammal, including a human, in need thereof, which comprises administering to such mammal an effective amount of a selected hydroxy-1-azo-naphthalene derivative.Type: GrantFiled: June 14, 2001Date of Patent: December 30, 2003Assignees: SmithKline Beecham Corporation, Ligand PharmaceuticalsInventors: Juan I. Luengo, Kevin J. Duffy, Stephen G. Miller
-
Patent number: 6642265Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: March 8, 2002Date of Patent: November 4, 2003Assignee: SmithKline Beecham CorporationInventors: Juan I. Luengo, Kevin J. Duffy
-
Patent number: 6630470Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.Type: GrantFiled: November 20, 2000Date of Patent: October 7, 2003Assignee: SmithKline Beecham CorporationInventors: Juan I Luengo, Kevin J Duffy
-
Patent number: 6600035Abstract: Compounds of formula (I) in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a) wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is 0, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration.Type: GrantFiled: May 24, 1995Date of Patent: July 29, 2003Assignee: SMithKline Beecham p.l.c.Inventors: Nigel John Perryman Broom, Frank Peter Harrington
-
Patent number: 6552008Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected azo-pyrazole derivative.Type: GrantFiled: March 22, 2002Date of Patent: April 22, 2003Assignee: SmithKline Beecham CorporationInventors: Kevin J. Duffy, Nannan Liu, Juan I. Luengo